In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin D levels

Circulation: Cardiovascular Genetics

Volumn 2, Issue 6, 2009, Pages 583-590

  Ohnishi, Mutsuko ^a   Nakatani, Teruyo ^a   Lanske, Beate ^a   Razzaque, M Shawkat ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcification; Klotho; NaPi2a; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; KLOTHO PROTEIN; PHOSPHATE; SODIUM PHOSPHATE COTRANSPORTER 2A; 1,25-DIHYDROXYVITAMIN D; BETA GLUCURONIDASE; DRUG DERIVATIVE; SLC34A1 PROTEIN, MOUSE; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; GENE INACTIVATION; GENETIC MANIPULATION; HYPERPHOSPHATASEMIA; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SOFT TISSUE CALCIFICATION; VITAMIN BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; BLOOD VESSEL; BONE; CALCINOSIS; FEMALE; GENETICS; HUMAN; HYPOPHOSPHATEMIA; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MUS;

ANIMALS; BLOOD VESSELS; BONE AND BONES; CALCINOSIS; CALCIUM; FEMALE; GLUCURONIDASE; HUMANS; HYPOPHOSPHATEMIA; MALE; MICE; MICE, KNOCKOUT; PHOSPHATES; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIA; VITAMIN D;

EID: 77449126558     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.108.847814     Document Type: Article

References (30)

1. Gaasbeek A, MeinDers AE. Hypophosphatemia: an upDate on its etiology and treatment. Am J Med. 2005;118:1094-1101.
2. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant. 2005;20: 2032-2035.
3. Memon F, El-Abbadi M, Nakatani T, Taguchi T, Lanske B, Razzaque MS. Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? Kidney Int. 2008;74: 566-570.
4. Chang Q, Hoefs S, Van Der Kemp AW, Topala CN, BinDels RJ, HoenDerop JG. The beta-glucuroniDase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310:490-493.
5. Nabeshima Y, Imura H. Alpha-Klotho: a regulator that integrates calcium homeostasis. Am J Nephrol. 2008;28:455-464.
6. Tsujikawa H, Kurotaki Y, Fujimori T, FukuDa K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003;17:2393-2403.
7. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse moDel. FASEB J. doi: 10.1096/fj.08-123992.
8. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, IiDa A, Shiraki-IiDa T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
9. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS. In vivo genetic eviDence for klotho-DepenDent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J. 2009;23: 433-441.
10. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B. Genetic eviDence of serum phosphate-inDepenDent functions of FGF-23 on bone. PLoS Genet. 2008;4:e1000154.
11. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA. 1998;95:5372-5377.
12. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J. 2006;20:720-722.
13. Liu D, Nazneen A, Taguchi T, Razzaque MS. Low-dose local kidney irradiation inhibits progression of experimental crescentic nephritis by promoting apoptosis. Am J Nephrol. 2008;28:555-568.
14. Zha Y, Taguchi T, Nazneen A, Shimokawa I, Higami Y, Razzaque MS. Genetic suppression of GH-IGF-1 activity, combined with lifelong caloric restriction, prevents age-related renal Damage and prolongs the life span in rats. Am J Nephrol. 2008;28:755-764.
15. Razzaque MS, Soegiarto DW, Chang D, Long F, Lanske B. Conditional Deletion of Indian hedgehog from collagen type 2alpha1-expressing cells results in abnormal endochondral bone formation. J Pathol. 2005;207: 453-461.
16. Razzaque MS, Taguchi T. Collagen-binding heat shock protein (HSP) 47 expression in anti-thymocyte serum (ATS)-induced glomerulonephritis. J Pathol. 1997;183:24-29.
17. Zha Y, Le VT, Higami Y, Shimokawa I, Taguchi T, Razzaque MS. Life-long suppression of growth hormone-insulin-like growth factor I activity in genetically altered rats could prevent age-related renal Damage. Endocrinology. 2006;147:5690-5698.
18. Razzaque MS, Nazneen A, Taguchi T. Immunolocalization of collagen and collagen-binding heat shock protein 47 in fibrotic lung diseases. Mod Pathol. 1998;11:1183-1188.
19. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med. 2006;12:298-305.
20. Miyamoto K, Ito M, Tatsumi S, Kuwahata M, Segawa H. New aspect of renal phosphate reabsorption: the type IIc sodium-DepenDent phosphate transporter. Am J Nephrol. 2007;27:503-515.
21. Tenenhouse HS. Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter. Annu Rev Nutr. 2005;25:197-214.
22. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by Deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009;75: 1166-1172.
23. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant. 2009;24:4-7.
24. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of Death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
26. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938 -2948.
27. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004;25:629-672.
28. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. doi: 10.1038/nrendo.2009.196.
29. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol. 2009;296:F470-F476.
30. Razzaque MS. Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? Nat Clin Pract Endocrinol Metab. 2007;3:788-789.